BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'- Find the Advantages of Careful Eating: Developing a Sound Connection with Food
- Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
- The Most Compelling Innovation Advancements Somewhat recently
- I took my shoes off and went for a barefoot hike. I couldn’t believe what happened next
- The Best 15 Applications for Efficiency and Association
- Moderna to complete US mRNA manufacturing network with $140 million investment
- America's Confided in Fridge in 2024
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
